Andrew Fordyce - Novozymes Executive VP of Food and Beverages
| NVZMF Stock | USD 52.71 1.79 3.28% |
EVP
Mr. Andrew Fordyce was Executive Vice President, Food Beverages at Novozymes AS since February 8, 2016. Previously, he was Executive Vice President of Business Operations at the Company from April 1, 2013 until February 8, 2016. He was previously Vice President of Sales and Customer Solutions. Since joining the Company in 1993, he has held several positions in commercial operations, research and development and production in Denmark, Switzerland and the United States. He is Board Member at CP Kelco. He holds a Doctorate of Philosophy degree in Chemical Engineering from the University of Texas at Austin. since 2016.
| Age | 55 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 45 44 46 00 00 |
| Web | https://www.novozymes.com |
Novozymes Management Efficiency
The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes' management efficiency ratios could be used to measure how well Novozymes manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 |
Novozymes AS B Leadership Team
Elected by the shareholders, the Novozymes' board of directors comprises two types of representatives: Novozymes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novozymes. The board's role is to monitor Novozymes' management team and ensure that shareholders' interests are well served. Novozymes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novozymes' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Videbaek, COO and Executive VP of Bus. Devel. | ||
| Tobias Bjorklund, Head of Investor Relations | ||
| Ester Baiget, Pres CEO | ||
| Kasim Kutay, Director | ||
| Anders Lund, Executive Vice President Household Care & Technical Industries | ||
| Agnete RaaschouNielsen, Director | ||
| Thomas Nagy, Executive VP of Supply Operations | ||
| Pedro Fernandes, Head America | ||
| Joergen Rasmussen, Independent Director | ||
| Andrew Fordyce, Executive VP of Food and Beverages | ||
| Lena Halskov, Director, Employee Representative | ||
| Tue Micheelsen, VP Marketing | ||
| Sebastian Sderberg, VP Acquisitions | ||
| Martin Riise, Head of Investor Relations | ||
| Peder Nielsen, CEO and Pres | ||
| Prisca HavranekKosicek, CFO | ||
| HeinzJuergen Bertram, Independent Director | ||
| Benny Loft, CFO and Executive VP | ||
| Anders Knudsen, Director, Employee Representative | ||
| Lena Olving, Independent Director | ||
| Mathias Uhlen, Independent Director | ||
| Graziela Malucelli, Supply Operations | ||
| Patricia Malarkey, Director | ||
| Henrik Gurtler, Chairman of the Board | ||
| Per Falholt, Consultant | ||
| Kim Stratton, Director | ||
| Tina Fanoe, Executive Vice President Agriculture & Bioenergy | ||
| Lena Holskov, Director, Employee Representative | ||
| Morten Rasmussen, Sustainability People | ||
| Thomas Bomhoff, Head of Investor Relations | ||
| Lars Green, Director | ||
| MSc MSc, Ex CFO | ||
| Lars Koeppler, Independent Director, Employee Representative |
Novozymes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novozymes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 222.86 M | |||
| Shares Owned By Insiders | 8.04 % | |||
| Shares Owned By Institutions | 42.30 % | |||
| Price To Earning | 33.38 X | |||
| Price To Book | 6.19 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS B. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |